2. Search Result
Search Result
Results for "

Moraxella catarrhalis

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-159688
    Cefditoren
    1 Publications Verification

    		 Antibiotic Bacterial Penicillin-binding protein (PBP) Interleukin Related Infection
    Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis .
    Cefditoren
  • HY-159687
    Nafithromycin

    WCK 4873

    		 Antibiotic Bacterial Infection
    Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter .
    Nafithromycin
  • HY-121195
    Apalcillin

    PC-904

    		 Bacterial Infection
    Apalcillin (PC-904) in combination with Ro 48-1220, a penam sulfone β-lactamase inhibitor, demonstrated broad-spectrum activity against gram-negative aerobic and anaerobic bacteria, excluding Klebsiella oxytoca. It exhibited potent activity against β-lactamase-producing Moraxella catarrhalis, Haemophilus influenzae, and Neisseria gonorrhoeae, with effective MICs (11 μg/mL). The combination also inhibited Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species at low MICs (0.25 to 4 μg/mL). However, its efficacy against oxacillin-resistant staphylococci and certain gram-positive organisms was limited. Apalcillin/Ro 48-1220 showed comparable efficacy to piperacillin/tazobactam against some extended-spectrum β-lactamase-producing Escherichia coli but was less effective against SHV-type β-lactamases .
    Apalcillin
  • HY-W744633
    Cefdaloxime

    		Drug Metabolite Bacterial Infection
    Cefdaloxime is an orally active cephalosporin and HR-916 ester metabolite. Cefdaloxime has a broad spectrum of activity against pathogens such as the majority of members of the family Enterobacteriaceae, staphylococci, Streptococcus spp., Neisseria gonorrhoeae, Moraxella catarrhalis, Haemophilus influenzae .
    Cefdaloxime
  • HY-123508
    PD 131628

    		Drug Metabolite Bacterial Infection
    PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC90s ranging from 0.004 to 0.008 mg/L .
    PD 131628
  • HY-125579
    Ro 25-0534

    		Bacterial Infection
    Ro 25-0534 is an antimicrobial compound against Pseudomonas. Ro 25-0534 is active against Enterobacteriaceae (MIC90: 0.06-2 μg/mL), Oxacillin (HY-B0465)-susceptible staphylococci, β-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC90: 1-2 μg/mL), Haemophilus influenzae (MIC90: 0.25-0.5 μg/mL), Moraxella catarrhalis (MIC90: 0.5 μg/mL), and most nonenteric Gram-negative bacilli (MIC90: 2-4 μg/mL) .
    Ro 25-0534
  • HY-111127
    LY164846

    		Antibiotic Bacterial Infection
    LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin (HY-B0522)-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin (HY-121544)-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections .
    LY164846
  • HY-105560
    Cefcanel

    		Bacterial Beta-lactamase Infection
    Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases .
    Cefcanel
  • HY-U00092A
    BAY-Y 3118 hydrochloride

    		Bacterial Infection
    BAY-Y 3118 hydrochloride is a quinolone antibacterial agent. BAY-Y 3118 hydrochloride has a broad antibacterial spectrum in vitro. BAY-Y 3118 hydrochloride exhibits high activity against gram-positive cocci and anaerobes. BAY-Y 3118 hydrochloride shows moderate activity against Enterobacteriaceae and Pseudomonas aeruginosa. BAY-Y 3118 hydrochloride can be used in the research of infectious diseases .
    BAY-Y 3118 hydrochloride
  • HY-181107
    DNA Gyrase/ribosomes-IN-1

    		Bacterial DNA/RNA Synthesis Cytochrome P450 Infection
    DNA Gyrase/ribosomes-IN-1 is a bacterial ribosome and DNA gyrase inhibitor, with IC50 values of 1.11 μM and 3.31 μM, respectively. DNA Gyrase/ribosomes-IN-1 also inhibits CYP3A4, with an IC50 of 18.5 μM, and exhibits stability in mouse plasma and liver microsomes. DNA Gyrase/ribosomes-IN-1 inhibits bacterial protein synthesis by interacting with ribosomal RNA and associated sites. DNA Gyrase/ribosomes-IN-1 suppresses bacterial DNA replication by interacting with the gyrase complex. DNA Gyrase/ribosomes-IN-1 restores activity against macrolide-resistant, erm-mediated Gram-positive pathogens and enhances activity against Gram-negative bacteria such as Haemophilus influenzae and Moraxella catarrhalis. DNA Gyrase/ribosomes-IN-1 can be used in research on community-acquired bacterial pneumonia .
    DNA Gyrase/ribosomes-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: